Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

17 Sept 2011

Abstract excerpt

T315I(+) Philadelphia chromosome-positive leukemias are inherently resistant to all licensed tyrosine kinase inhibitors, and therapeutic options remain limited. We report the outcome of allogeneic stem cell transplantation in 64 patients with documented BCR-ABL(T315I) mutations. Median follow-up was 52 months from mutation detection and 26 months from transplantation. At transplantation, 51.5% of patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21926354
DOI: 10.1182/blood-2011-07-367326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasPMID 21926354Read ↗

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.Semantic proximity Read ↗

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.Semantic proximity Read ↗

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.Semantic proximity Read ↗

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation–related imatinib failureSemantic proximity Read ↗

The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Semantic proximity Read ↗

[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].Semantic proximity Read ↗

Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Semantic proximity Read ↗

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.Semantic proximity Read ↗

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia.Semantic proximity Read ↗

Chronic Myeloid Leukemia Stem CellsSemantic proximity Read ↗

[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.